<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FANAPT- iloperidoneÂ tabletÂ </strong><br><strong>FANAPT- iloperidoneÂ 
			Â </strong><br>Novartis Pharmaceuticals Corporation<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use FANAPT safely and effectively. See full prescribing information for FANAPT.</span><br><br><span class="Bold">FANAPTÂ®Â (iloperidone) tablets</span><br><span class="Bold">Initial U.S. Approval: 2009</span><br>
</div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></span><span class="Bold">Â </span>
</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. FANAPT is not approved for use in patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. (<a href="#s5p1">5.1</a>)</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Dosage and Administration (<a href="#s2p2">2.2</a>) 
		Â Â Â Â Â 
	4/2014 </p></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></span><span class="Bold">Â </span>
</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. FANAPT is not approved for use in patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. (<a href="#s5p1">5.1</a>)</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">FANAPT is anÂ atypical antipsychotic agent indicated for the treatment of schizophreniaÂ in adults. (<a href="#s1">1</a>) Efficacy was established in two short-term (4- and 6-week) placebo- and active-controlled studies of adult patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. (<a href="#s14">14</a>) In choosing among treatments, prescribers should consider the ability of FANAPT to prolong the QT interval and theÂ use of other drugs first.Â Prescribers should also consider the need to titrate FANAPT slowly to avoid <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, which may lead to delayed effectiveness compared to some other drugs that do not require similar titration.Â  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">The recommended target dosage of FANAPT tablets is 12 to 24 mg/day administered twice daily. This target dosage range is achieved by daily dosage adjustments, alerting patients to symptoms of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, startingÂ at a dose of 1 mg twice daily, then moving to 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12Â mg twice daily on Days 2, 3, 4, 5, 6, and 7 respectively, to reach the 12 mg/day to 24 mg/day dose range.Â FANAPT can be administered without regard to meals. (<a href="#s2p1">2.1</a>) </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg tablets. (<a href="#s3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to FANAPT or to any components in the formulation. (<a href="#s4">4</a>)Â  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span></span> who are treated with atypical antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and cerebrovascular-related adverse events, including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. (<a href="#s5p1">5.1</a>)</li>
<li>
<span class="Italics">QT prolongation:</span> Prolongs QT interval and may be associated with <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>-consider using other antipsychotics first. Avoid use of FANAPT in combination with other drugs that are known to prolong QTc; use caution and consider dose modification when prescribing FANAPT with other drugs that inhibit FANAPT metabolism.Â Monitor serum potassium and magnesium in patients at risk for <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span>.Â (<a href="#s1">1</a>, <a href="#s5p2">5.2</a>, <a href="#s7p1">7.1</a>, <a href="#s7p3">7.3</a>, <a href="#s12p3">12.3</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span>: </span>Manage with immediate discontinuation of drug and close monitoring. (<a href="#s5p3">5.3</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive dyskinesia</span>: </span>Discontinue if clinically appropriate. (<a href="#s5p4">5.4</a>)</li>
<li>
<span class="Italics">Metabolic Changes: </span>Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. (<a href="#s5p5">5.5</a>)
			<ul class="Circle">
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus: </span>Monitor patients for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> including <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Monitor glucose regularly in patients at risk for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. (<a href="#s5p5">5.5</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>: </span>Undesirable alterations have been observed in patients treated with atypical antipsychotics. (<a href="#s5p5">5.5</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span>: </span><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> has been reported. Monitor weight. (<a href="#s5p5">5.5</a>)</li>
</ul>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>:</span> Use cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or with conditions that lower <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. (<a href="#s5p6">5.6</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span>: </span><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> can occur with standing. (<a href="#s5p7">5.7</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></span> have been reported with antipsychotics. Patients with a pre-existing low white blood cell count (WBC) or a history of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should have their complete blood count (CBC) monitored frequently during the first few months of therapy and should discontinue FANAPT at the first sign of a decline in WBC in the absence of other causative factors. (<a href="#s5p8">5.8</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span>:</span> Close supervision of high risk patients. (<a href="#s5p12">5.12</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span>:</span> Cases have been reported in association with FANAPT treatment. (<a href="#s5p13">5.13</a>)</li>
<li>
<span class="Italics">Potential for cognitive and motor impairment:</span> Use caution when operating machinery. (<a href="#s5p14">5.14</a>)</li>
<li>See Full Prescribing Information for additional <span class="Italics">WARNINGS and PRECAUTIONS.</span>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Commonly observed adverse reactionsÂ (incidence â‰¥5% and 2-fold greater than placebo) were: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span>. (<a href="#s6p1">6.1</a>)  </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc"><li>The dose of FANAPT should be reduced in patients co-administered a strong CYP2D6 or CYP3A4 inhibitor. (<a href="#s2p2">2.2</a>, <a href="#s7p1">7.1</a>)</li></ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Pregnancy: No human or animal data.Â Use only if clearly needed. (<a href="#s8p1">8.1</a>)<br>
</li>
<li>Nursing Mothers: Should not breastfeed. (<a href="#s8p3">8.3</a>)<br>
</li>
<li>Pediatric Use: Safety and effectiveness not established in children and adolescents. (<a href="#s8p4">8.4</a>)<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: FANAPT is not recommended for patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#s2p2">2.2</a>, <a href="#s8p7">8.7</a>)<br>
</li>
<li>The dose of FANAPT should be reduced in patients who are poor metabolizers of CYP2D6. (<a href="#s2p2">2.2</a>, <a href="#s12p3">12.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 4/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></span></a></h1>
<h1><a href="#section-1" class="toc">1Â Â Â Â Â INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2Â Â Â Â Â DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1Â Â Â Â Â Usual Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2Â Â Â Â Â Dosage in Special Populations</a></h2>
<h2><a href="#section-2.3" class="toc">2.3Â Â Â Â Â Maintenance Treatment</a></h2>
<h2><a href="#section-2.4" class="toc">2.4Â Â Â Â Â Reinitiation of Treatment in Patients Previously Discontinued</a></h2>
<h2><a href="#section-2.5" class="toc">2.5Â Â Â Â Â Switching from Other Antipsychotics</a></h2>
<h1><a href="#section-3" class="toc">3Â Â Â Â Â DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4Â Â Â Â Â CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5Â Â Â Â Â WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1Â Â Â Â Â Increased Risks in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2Â Â Â Â Â QT Prolongation</a></h2>
<h2><a href="#section-5.3" class="toc">5.3Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)</a></h2>
<h2><a href="#section-5.4" class="toc">5.4Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5Â Â Â Â Â Metabolic Changes</a></h2>
<h2><a href="#section-5.6" class="toc">5.6Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10Â Â Â Â Â Body Temperature Regulation</a></h2>
<h2><a href="#section-5.11" class="toc">5.11Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.13Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span></a></h2>
<h2><a href="#section-5.14" class="toc">5.14Â Â Â Â Â Potential for Cognitive and Motor Impairment</a></h2>
<h1><a href="#section-6" class="toc">6Â Â Â Â Â ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1Â Â Â Â Â Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2Â Â Â Â Â Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7Â Â Â Â Â DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1Â Â Â Â Â Potential for Other Drugs to Affect FANAPT</a></h2>
<h2><a href="#section-7.2" class="toc">7.2Â Â Â Â Â Potential for FANAPT to Affect Other Drugs</a></h2>
<h2><a href="#section-7.3" class="toc">7.3Â Â Â Â Â Drugs that Prolong the QT Interval</a></h2>
<h1><a href="#section-8" class="toc">8Â Â Â Â Â USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1Â Â Â Â Â Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2Â Â Â Â Â Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3Â Â Â Â Â Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4Â Â Â Â Â Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5Â Â Â Â Â Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.8" class="toc">8.8Â Â Â Â Â Smoking Status</a></h2>
<h1><a href="#section-9" class="toc">9Â Â Â Â Â DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1Â Â Â Â Â Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2Â Â Â Â Â Abuse</a></h2>
<h1><a href="#section-10" class="toc">10Â Â Â Â Â OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1Â Â Â Â Â Human Experience</a></h2>
<h2><a href="#section-10.2" class="toc">10.2Â Â Â Â Â Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></a></h2>
<h1><a href="#section-11" class="toc">11Â Â Â Â Â DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12Â Â Â Â Â CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1Â Â Â Â Â Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2Â Â Â Â Â Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3Â Â Â Â Â Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13Â Â Â Â Â NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1Â Â Â Â Â Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14Â Â Â Â Â CLINICAL STUDIES</a></h1>
<h1><a href="#section-15" class="toc">16Â Â Â Â Â HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17Â Â Â Â Â PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1Â Â Â Â Â QT Interval Prolongation</a></h2>
<h2><a href="#section-16.2" class="toc">17.2Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></a></h2>
<h2><a href="#section-16.3" class="toc">17.3Â Â Â Â Â Metabolic Changes</a></h2>
<h2><a href="#section-16.4" class="toc">17.4Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></a></h2>
<h2><a href="#section-16.5" class="toc">17.5Â Â Â Â Â Interference with Cognitive and Motor Performance</a></h2>
<h2><a href="#section-16.6" class="toc">17.6Â Â Â Â Â Pregnancy</a></h2>
<h2><a href="#section-16.7" class="toc">17.7Â Â Â Â Â Nursing</a></h2>
<h2><a href="#section-16.8" class="toc">17.8Â Â Â Â Â Concomitant Medication</a></h2>
<h2><a href="#section-16.9" class="toc">17.9Â Â Â Â Â Alcohol</a></h2>
<h2><a href="#section-16.10" class="toc">17.10Â Â Â Â Â Heat Exposure and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-1"></a><p></p>
<h1><span class="Bold">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></span></h1>
<p class="First"><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Analysis of seventeen placebo-controlled trials (modal duration 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in the drug-treated patients of between 1.6 to 1.7 times the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were varied, most of the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> appeared to be either cardiovascular (e.g., <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>) or infectious (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>) in nature.</span></p>
<p><span class="Bold">Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. FANAPT is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>.</span><span class="Bold Italics"> [See Warnings and Precautions (5.1)]</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1Â Â Â Â Â INDICATIONS AND USAGE</h1>
<p class="First">FANAPT<span class="Sup">Â®</span>Â tablets are indicated for the treatment of adults with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. Efficacy was established in two short-term (4- and 6-week) placebo and active-controlled studies of adult patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> <span class="Italics">[see Clinical Studies (14)]</span>.</p>
<p>When deciding among the alternative treatments available for this condition, the prescriber should consider the finding that FANAPT<span class="Sup">Â </span>is associated with prolongation of the QTc interval <span class="Italics">[see Warnings and Precaution</span><span class="Italics">s</span><span class="Italics"> (5.2)]</span>.Â Prolongation of the QTc interval is associated in some other drugs with the ability to cause <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>-type <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, a potentially fatal <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">polymorphic ventricular tachycardia</span> which can result in <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>.Â In many cases this would lead to the conclusion that other drugs should be tried first.Â Whether FANAPTÂ will cause <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> or increase the rate of <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> is not yet known.</p>
<p>Patients must be titrated to an effective dose of FANAPT.<span class="Sup">Â </span>Thus, control of symptoms may be delayed during the first 1 to 2 weeks of treatment compared to some other antipsychotic drugs that do not require a similar titration.Â Prescribers should be mindful of this delay when selecting an antipsychotic drug for the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> <span class="Italics">[</span><span class="Italics">s</span><span class="Italics">ee Dosage and Administration (2.1) and Clinical Studies (14)]</span>.</p>
<p>The effectiveness of FANAPTÂ in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials.Â Therefore, the physician who elects to use FANAPTÂ for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient <span class="Italics">[s</span><span class="Italics">ee Dosage and Administration (2.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2Â Â Â Â Â DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p1"></a><a name="section-2.1"></a><p></p>
<h2>2.1Â Â Â Â Â Usual Dose</h2>
<p class="First">FANAPT must be titrated slowly from a low starting dose to avoid <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> due to its alpha-adrenergic blocking properties. The recommended starting dose for FANAPT tablets is 1 mg twice daily. Dose increases to reach the target range of 6 to 12 mg twice daily (12 to 24 mg/day) may be made with daily dosage adjustments not to exceed 2 mg twice daily (4 mg/day). The maximum recommended dose is 12 mg twice daily (24 mg/day). FANAPT doses above 24 mg/day have not been systematically evaluated in the clinical trials. Efficacy was demonstrated with FANAPT in a dose range of 6 to 12 mg twice daily. Prescribers should be mindful of the fact that patients need to be titrated to an effective dose of FANAPT. Thus, control of symptoms may be delayed during the first 1 to 2 weeks of treatment compared to some other antipsychotic drugs that do not require similar titration. Prescribers should also be aware that some adverse effects associated with FANAPT use are dose related.</p>
<p>FANAPT can be administered without regard to meals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p2"></a><a name="section-2.2"></a><p></p>
<h2>2.2Â Â Â Â Â Dosage in Special Populations</h2>
<p class="First">Dosage adjustments are not routinely indicated on the basis of age, gender, race, or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> status <span class="Italics">[see Use in Specific Populations (8.6, 8.7)]</span>.</p>
<p><span class="Bold Italics">Dosage adjustment for patients taking FANAPT concomitantly with potential CYP2D6 inhibitors:</span>Â FANAPT dose should be reduced by one-half when administered concomitantly with strong CYP2D6 inhibitors such as fluoxetine or paroxetine.Â When the CYP2D6 inhibitor is withdrawn from the combination therapy, FANAPT dose should then be increasedÂ to where it was before <span class="Italics">[see Drug Interactions (7.1)]</span>.</p>
<p><span class="Bold Italics">Dosage adjustment for patients taking FANAPT concomitantly with potential CYP3A4 inhibitors:</span>Â FANAPT dose should be reduced by one-half when administered concomitantly with strong CYP3A4 inhibitors such as ketoconazole or clarithromycin.Â When the CYP3A4 inhibitor is withdrawn from the combination therapy, FANAPT dose should be increased to where it was beforeÂ <span class="Italics">[see Drug Interactions (7.1)]</span>.</p>
<p><span class="Bold Italics">Dosage adjustment for patients taking FANAPT who are poor metabolizers of CYP2D6:</span> FANAPT dose should be reduced by one-half for poor metabolizers of CYP2D6 <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span>
									Â No dose adjustment to FANAPT is needed in patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.  Exercise caution when administering it to patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.  FANAPT is not recommended for patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Use in Specific Populations (8.7)]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p3"></a><a name="section-2.3"></a><p></p>
<h2>2.3Â Â Â Â Â Maintenance Treatment</h2>
<p class="First">Although there is no body of evidence available to answer the question of how long the patient treated with FANAPT should be maintained, it is generally recommended that responding patients be continued beyond the acute response. Patients should be periodically reassessed to determine the need for maintenance treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p4"></a><a name="section-2.4"></a><p></p>
<h2>2.4Â Â Â Â Â Reinitiation of Treatment in Patients Previously Discontinued</h2>
<p class="First">Although there are no data to specifically address reinitiation of treatment, it is recommended that the initiation titration schedule be followed whenever patients have had an interval off FANAPTÂ of more than 3 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2p5"></a><a name="section-2.5"></a><p></p>
<h2>2.5Â Â Â Â Â Switching from Other Antipsychotics</h2>
<p class="First">There are no specific data to address how patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> can be switched from other antipsychotics to FANAPT or how FANAPT can be used concomitantly with other antipsychotics.Â Although immediate discontinuation of the previous antipsychotic treatment may be acceptable for some patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, more gradual discontinuation may be most appropriate for others.Â In all cases, the period of overlapping antipsychotic administration should be minimized.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>3Â Â Â Â Â DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">FANAPT tablets are available in the following strengths: 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg.Â The tablets are white, round, flat, beveled-edged and identified with a logo â€œ<img alt="Tablet Imprint " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=43452bf8-76e7-47a9-a5d8-41fe84d061f0&amp;name=fanapt-01.jpg">â€? debossed on one side and tablet strength â€œ1â€?, â€œ2â€?, â€œ4â€?, â€œ6â€?, â€œ8â€?, â€œ10â€?, or â€œ12â€? debossed on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>4Â Â Â Â Â CONTRAINDICATIONS</h1>
<p class="First">FANAPT is contraindicated in individuals with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> toÂ the product.Â Reactions have included <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span><span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>5Â Â Â Â Â WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p1"></a><a name="section-5.1"></a><p></p>
<h2>5.1Â Â Â Â Â Increased Risks in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></h2>
<p class="First"><span class="Bold">Increased Mortality</span></p>
<p><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with atypical antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> compared to placebo. </span><span class="Bold">FANAPT </span><span class="Bold">is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span></span><span class="Bold">Â </span><span class="Bold Italics">[s</span><span class="Bold Italics">ee Boxed Warning</span><span class="Bold Italics">]</span><span class="Bold">.</span></p>
<p><span class="Bold">Cerebrovascular Adverse Events, Including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></span></p>
<p>In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, there was a higher incidence of cerebrovascular adverse events (<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accidents</span> and <span class="product-label-link" type="condition" conceptid="373503" conceptname="Transient cerebral ischemia">transient ischemic attacks</span>) including fatalities compared to placebo-treated patients.Â FANAPT is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related psychosisÂ <span class="Italics">[s</span><span class="Italics">ee Boxed Warning</span><span class="Italics">]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p2"></a><a name="section-5.2"></a><p></p>
<h2>5.2Â Â Â Â Â QT Prolongation</h2>
<p class="First">In an open-label QTc study in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">schizoaffective disorder</span> (n=160), FANAPT was associated with QTc prolongation of 9 msec at an iloperidone dose of 12 mg twice daily.Â The effect of FANAPT on the QT interval was augmented by the presence of CYP450 2D6 or 3A4 metabolic inhibition (paroxetine 20Â mg once daily and ketoconazole 200Â mg twice daily, respectively).Â Under conditions of metabolic inhibition for both 2D6 and 3A4, FANAPT 12 mg twice daily was associated with a mean QTcF increase from baseline of about 19 msec.</p>
<p>No cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> or other severe <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> were observed during the pre-marketing clinical program.</p>
<p>The use of FANAPT should be avoided in combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval (e.g., pentamidine, levomethadyl acetate, methadone).Â FANAPT should also be avoided in patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span> and in patients with a history of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</p>
<p>Certain circumstances may increase the risk of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> and/or <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> in association with the use of drugs that prolong the QTc interval, including (1) <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>; (2) <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval; (5) recent <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>; and/or (6) uncompensated <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.Â </p>
<p>Caution is warranted when prescribing FANAPT with drugs that inhibit FANAPT metabolism <span class="Italics">[see Drug Interaction</span><span class="Italics">s</span><span class="Italics"> (7.1)]</span>, and in patients with reduced activity of CYP2D6 <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
<p>It is recommended that patients being considered for FANAPT treatment who are at risk for significant <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span> have baseline serum potassium and magnesium measurements with periodic monitoring. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> (and/or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>) may increase the risk of QT prolongation and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>.Â FANAPT should be avoided in patients with histories of significant cardiovascular illness, e.g., QT prolongation, recent <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, uncompensated <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>.Â FANAPT should be discontinued in patients who are found to have persistent QTc measurements &gt;500 msec.</p>
<p>If patients taking FANAPT experience symptoms that could indicate the occurrence of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, e.g., <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, the prescriber should initiate further evaluation, including cardiac monitoring.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p3"></a><a name="section-5.3"></a><p></p>
<h2>5.3Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)</h2>
<p class="First">A potentially fatal symptom complex sometimes referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in association with administration of antipsychotic drugs, including FANAPT. Clinical manifestations include <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status (including <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonic</span> signs) and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> (<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>), and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.</p>
<p>The diagnostic evaluation of patients with this syndrome is complicated.Â In arriving at a diagnosis, it is important to identify cases in which the clinical presentation includes both serious medical illness (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS).Â Other important considerations in the differential diagnosis include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, and primary central nervous system (CNS) pathology.</p>
<p>The management of this syndrome should include: (1) immediate discontinuation of the antipsychotic drugs and other drugs not essential to concurrent therapy, (2) intensive symptomatic treatment and medical monitoring, and (3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for NMS.</p>
<p>If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered.Â The patient should be carefully monitored, since recurrences of NMS have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p4"></a><a name="section-5.4"></a><p></p>
<h2>5.4Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive dyskinesia</span> is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements, which may develop in patients treated with antipsychotic drugs.Â Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely on prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> is unknown.</p>
<p>The risk of developing <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic administered increases. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.</p>
<p>There is no known treatment for established cases of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.Â Antipsychotic treatment itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process.Â The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.</p>
<p>Given these considerations, FANAPT should be prescribed in a manner that is most likely to minimize the occurrence of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>.Â Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate.Â In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought.Â The need for continued treatment should be reassessed periodically.</p>
<p>If signs and symptoms of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> appear in a patient on FANAPT, drug discontinuation should be considered.Â However, some patients may require treatment with FANAPT despite the presence of the syndrome. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p5"></a><a name="section-5.5"></a><p></p>
<h2>5.5Â Â Â Â Â Metabolic Changes</h2>
<p class="First">
									Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> <span class="Italics">[see Patient Counseling Information (17.3)]</span>. While all atypical antipsychotic drugs have been shown to produce some metabolic changes, each drug in the class has its own specific risk profile. 
								</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</span></p>
<p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, in some cases extreme and associated with <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span> or hyperosmolar <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has been reported in patients treated with atypical antipsychotics including FANAPT.Â Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and the increasing incidence of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in the general population.Â Given these confounders, the relationship between atypical antipsychotic use and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse events in patients treated with the atypical antipsychotics included in these studies.Â Because FANAPT was not marketed at the time these studies were performed, it is not known if FANAPT is associated with this increased risk.</p>
<p>Patients with an established diagnosis of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control.Â Patients with risk factors for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (e.g., <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, family history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment.Â Any patient treated with atypical antipsychotics should be monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> including <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>.Â Patients who develop symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> during treatment with atypical antipsychotics should undergo fasting blood glucose testing.Â In some cases, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug.</p>
<p>Data from a 4-week, fixed-dose study in adult subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, in which fasting blood samples were drawn, are presented in Table 1. </p>
<table>
<caption><span>Table 1: Change in Fasting Glucose</span></caption>
<col width="355">
<col width="275">
<col width="275">
<tbody class="Headless">
<tr class="First">
<td align="center"></td>
<td align="center"></td>
<td align="center"><span class="Bold">FANAPT
												</span></td>
</tr>
<tr>
<td align="center"></td>
<td align="center"><span class="Bold">Placebo</span></td>
<td align="center"><span class="Bold">24 mg/day</span></td>
</tr>
<tr>
<td align="center"></td>
<td class="Toprule" align="center" colspan="2"><span class="Bold">Mean Change from Baseline(mg/dL)</span></td>
</tr>
<tr>
<td align="center"></td>
<td align="center"><span class="Bold">n=114</span></td>
<td align="center"><span class="Bold">n=228</span></td>
</tr>
<tr>
<td align="center"><span class="Bold">Serum Glucose Change from Baseline </span></td>
<td align="center">-0.5</td>
<td align="center">6.6</td>
</tr>
<tr>
<td align="center"></td>
<td align="center" colspan="2"><span class="Bold">Proportion of Patients with Shifts</span></td>
</tr>
<tr>
<td align="center"><span class="Bold">Serum Glucose Normal to High</span></td>
<td align="center">2.5 %</td>
<td align="center">10.7 %</td>
</tr>
<tr class="Last">
<td align="center">(&lt;100 mg/dL to â‰¥126 mg/dL)</td>
<td align="center">(2/80)</td>
<td align="center">(18/169)</td>
</tr>
</tbody>
</table>
<p>
									Pooled analyses of glucose data from clinical studies including longer term trials are shown in Table 2.
								</p>
<table>
<caption><span>Table 2: Change in Glucose</span></caption>
<col width="200">
<col width="235">
<col width="235">
<col width="235">
<tbody class="Headless">
<tr class="First"><td align="center" colspan="4"><span class="Bold">Mean Change from Baseline (mg/dL)</span></td></tr>
<tr>
<td class="Toprule"></td>
<td class="Toprule" align="center"><span class="Bold">3-6 months</span></td>
<td class="Toprule" align="center"><span class="Bold">6-12 months</span></td>
<td class="Toprule" align="center"><span class="Bold">&gt;12 months</span></td>
</tr>
<tr>
<td align="left">FANAPT 10-16 mg/day</td>
<td align="center">1.8 (N=773)</td>
<td align="center">5.4 (N=723)</td>
<td align="center">5.4 (N=425)</td>
</tr>
<tr class="Last">
<td align="left">FANAPT 20-24 mg/day</td>
<td align="center">-3.6 (N=34)</td>
<td align="center">-9.0 (N=31)</td>
<td align="center">-18.0 (N=20)</td>
</tr>
</tbody>
</table>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></span></p>
<p>
									Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.</p>
<p>
									Data from a placebo-controlled, 4-week, fixed-dose study, in which fasting blood samples were drawn, in adult subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> are presented in Table 3.
								</p>
<table>
<caption><span>Table 3: Change in Fasting Lipids</span></caption>
<col width="405">
<col width="250">
<col width="250">
<tbody class="Headless">
<tr class="First">
<td align="center"></td>
<td align="center"></td>
<td align="center"><span class="Bold">FANAPT
												</span></td>
</tr>
<tr>
<td align="center"></td>
<td align="center"><span class="Bold">Placebo </span></td>
<td align="center"><span class="Bold">24 mg/day</span></td>
</tr>
<tr>
<td align="center"></td>
<td class="Toprule" align="center" colspan="2"><span class="Bold">Mean Change from Baseline (mg/dL)</span></td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></span></td>
<td align="center"><span class="Bold">n=114</span></td>
<td align="center"><span class="Bold">n=228 </span></td>
</tr>
<tr>
<td align="left"><span class="Bold">Change from baseline</span></td>
<td align="center">-2.17</td>
<td align="center">8.18</td>
</tr>
<tr>
<td align="left"><span class="Bold">LDL</span></td>
<td align="center"><span class="Bold">n=109</span></td>
<td align="center"><span class="Bold">n=217</span></td>
</tr>
<tr>
<td align="left"><span class="Bold">Change from baseline</span></td>
<td align="center">-1.41</td>
<td align="center">9.03</td>
</tr>
<tr>
<td align="left"><span class="Bold">HDL</span></td>
<td align="center"><span class="Bold">n=114</span></td>
<td align="center"><span class="Bold">n=228</span></td>
</tr>
<tr>
<td align="left"><span class="Bold">Change from baseline</span></td>
<td align="center">-3.35</td>
<td align="center">0.55</td>
</tr>
<tr>
<td align="left"><span class="Bold">Triglycerides</span></td>
<td align="center"><span class="Bold">n=114</span></td>
<td align="center"><span class="Bold">n=228 </span></td>
</tr>
<tr>
<td align="left"><span class="Bold">Change from baseline</span></td>
<td align="center">16.47</td>
<td align="center">-0.83</td>
</tr>
<tr>
<td align="left"></td>
<td align="center" colspan="2"><span class="Bold">Proportion of Patients with Shifts</span></td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></span></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Bold">Normal to High</span></td>
<td align="center">1.4%</td>
<td align="center">3.6%</td>
</tr>
<tr>
<td align="left"><span class="Bold">(&lt;200 mg/dL to â‰¥240 mg/dL)</span></td>
<td align="center">(1/72)</td>
<td align="center">(5/141)</td>
</tr>
<tr>
<td align="left"><span class="Bold">LDL</span></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Bold">Normal to High</span></td>
<td align="center">2.4%</td>
<td align="center">1.1%</td>
</tr>
<tr>
<td align="left"><span class="Bold">(&lt;100 mg/dL to â‰¥160 mg/dL)</span></td>
<td align="center">(1/42)</td>
<td align="center">(1/90)</td>
</tr>
<tr>
<td align="left"><span class="Bold">HDL</span></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Bold">Normal to Low</span></td>
<td align="center">23.8%</td>
<td align="center">12.1%</td>
</tr>
<tr>
<td align="left"><span class="Bold">( â‰¥40 mg/dL to &lt;40 mg/dL)</span></td>
<td align="center">(19/80)</td>
<td align="center">(20/166)</td>
</tr>
<tr>
<td align="left"><span class="Bold">Triglycerides</span></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Bold">Normal to High</span></td>
<td align="center">8.3%</td>
<td align="center">10.1%</td>
</tr>
<tr class="Last">
<td align="left"><span class="Bold">(&lt;150 mg/dL to â‰¥200 mg/dL)</span></td>
<td align="center">(6/72)</td>
<td align="center">(15/148)</td>
</tr>
</tbody>
</table>
<p>
									Pooled analyses of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglyceride data from clinical studies including longer term trials are shown in Tables 4 and 5.
								</p>
<table>
<caption><span>Table 4: Change in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></span></caption>
<col width="200">
<col width="235">
<col width="235">
<col width="235">
<tbody class="Headless">
<tr class="First"><td class="Toprule" align="center" colspan="4"><span class="Bold">Mean Change from Baseline (mg/dL)</span></td></tr>
<tr>
<td class="Toprule"></td>
<td class="Toprule" align="center"><span class="Bold">3-6 months</span></td>
<td class="Toprule" align="center"><span class="Bold">6-12 months</span></td>
<td class="Toprule" align="center"><span class="Bold">&gt;12 months</span></td>
</tr>
<tr>
<td align="left">FANAPT 10-16 mg/day</td>
<td align="center">-3.9 (N=783)</td>
<td align="center">-3.9 (N=726)</td>
<td align="center">-7.7 (N=428)</td>
</tr>
<tr class="Last">
<td align="left">FANAPT 20-24 mg/day</td>
<td align="center">-19.4 (N=34)</td>
<td align="center">-23.2 (N=31)</td>
<td align="center">-19.4 (N=20)</td>
</tr>
</tbody>
</table>
<table>
<caption><span>Table 5: Change in Triglycerides</span></caption>
<col width="200">
<col width="235">
<col width="235">
<col width="235">
<tbody class="Headless">
<tr class="First"><td class="Toprule" align="center" colspan="4"><span class="Bold">Mean Change from Baseline (mg/dL)</span></td></tr>
<tr>
<td class="Toprule"></td>
<td class="Toprule" align="center"><span class="Bold">3-6 months</span></td>
<td class="Toprule" align="center"><span class="Bold">6-12 months</span></td>
<td class="Toprule" align="center"><span class="Bold">&gt;12 months</span></td>
</tr>
<tr>
<td align="left">FANAPT 10-16 mg/day</td>
<td align="center">-8.9 (N=783)</td>
<td align="center">-8.9 (N=726)</td>
<td align="center">-17.7 (N=428)</td>
</tr>
<tr class="Last">
<td align="left">FANAPT 20-24 mg/day</td>
<td align="center">-26.6 (N=34)</td>
<td align="center">-35.4 (N=31)</td>
<td align="center">-17.7 (N=20)</td>
</tr>
</tbody>
</table>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></span></p>
<p>
									<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.
								</p>
<p>
									Across all short- and long-term studies, the overall mean change from baseline at endpoint was 2.1 kg.
								</p>
<p>
									Changes in body weight (kg) and the proportion of subjects with â‰¥7% gain in body weight from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies in adult subjects are presented in Table 6.
								</p>
<table>
<caption><span>Table 6: Change in Body Weight</span></caption>
<col width="380">
<col width="175">
<col width="175">
<col width="175">
<tbody class="Headless">
<tr class="First">
<td align="left"></td>
<td align="left"></td>
<td align="center"><span class="Bold">FANAPT</span></td>
<td align="center"><span class="Bold">FANAPT</span></td>
</tr>
<tr>
<td align="left"></td>
<td align="center"><span class="Bold">Placebo</span></td>
<td align="center"><span class="Bold">10-16 mg/day</span></td>
<td align="center"><span class="Bold">20-24 mg/day</span></td>
</tr>
<tr>
<td align="left"></td>
<td align="center">n=576</td>
<td align="center">n=481</td>
<td align="center">n=391</td>
</tr>
<tr>
<td class="Toprule" align="left"><span class="Bold">Weight (kg)</span></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
</tr>
<tr>
<td align="left"><span class="Bold">Change from Baseline</span></td>
<td align="center">-0.1</td>
<td align="center">2.0</td>
<td align="center">2.7</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></span></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr class="Last">
<td align="left"><span class="Bold">â‰¥7% increase from Baseline</span></td>
<td align="center">4%</td>
<td align="center">12%</td>
<td align="center">18%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p6"></a><a name="section-5.6"></a><p></p>
<h2>5.6Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First">In short-term placebo-controlled trials (4- to 6-weeks), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> occurred in 0.1% (1/1344) of patientsÂ treated with FANAPT compared to 0.3% (2/587) on placebo.Â As with other antipsychotics, FANAPT should be used cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or with conditions that potentially lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold, e.g., Alzheimerâ€™s <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>.Â Conditions that lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold may be more prevalent in a population of 65 years or older.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p7"></a><a name="section-5.7"></a><p></p>
<h2>5.7Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></h2>
<p class="First">FANAPTÂ can induce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> associated with <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.Â This reflects its alpha1-adrenergic antagonist properties. In double-blind placebo-controlled short-term studies, where the dose was increased slowly, as recommended above, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> was reported in 0.4% (5/1344) of patients treated with FANAPT, compared with 0.2% (1/587) on placebo.Â <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span> was reported in 5% of patients given 20 to 24 mg/day, 3% of patients given 10 to 16 mg/day, and 1% of patients given placebo.Â More rapid titration would be expected to increase the rate of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.Â </p>
<p>FANAPT should be used with caution in patients with known cardiovascular disease (e.g., <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, or conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (<span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, and treatment with antihypertensive medications). Monitoring of orthostatic vital signs should be considered in patients who are vulnerable to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p8"></a><a name="section-5.8"></a><p></p>
<h2>5.8Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></h2>
<p class="First">In clinical trial and postmarketing experience, events of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> have been reported temporally related to antipsychotic agents.Â <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> (including fatal cases) has also been reported. </p>
<p>Possible risk factors for <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> include preexisting low white blood cell count (WBC) and history of drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. Patients with a pre-existing low WBC or a history of drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should have their complete blood count (CBC) monitored frequently during the first few months of therapy and should discontinue FANAPT at the first sign of a decline in WBC in the absence of other causative factors. </p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should be carefully monitored for <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other symptoms or signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and treated promptly if such symptoms or signs occur. Patients with severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (absolute neutrophil count &lt;1000/mm<span class="Sup">3</span>) should discontinue FANAPT and have their WBC followed until recovery.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p9"></a><a name="section-5.9"></a><p></p>
<h2>5.9Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span></h2>
<p class="First">As with other drugs that antagonize dopamine D2 receptors, FANAPT elevates prolactin levels.Â </p>
<p><span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span> may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion.Â This, in turn, may inhibit reproductive function by impairing gonadalsteroidogenesis in both female and male patients.Â <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">Galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> have been reported with prolactin-elevating compounds.Â Long-standing <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span> when associated with <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> may lead to decreased bone density in both female and male patients. </p>
<p>Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent <span class="Italics">in vitro</span>, a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer. Mammary gland proliferative changes and increases in serum prolactin were seen in mice and rats treated with FANAPTÂ <span class="Italics">[see Nonclinical Toxicology (13.1)]</span>. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at this time.</p>
<p>In a short-term placebo-controlled trial (4-weeks), the mean change from baseline to endpoint in plasma prolactin levels for the FANAPT 24 mg/day-treated group was an increase of 2.6 ng/mL compared to a decrease of 6.3 ng/mL in the placebo-group.Â In this trial, elevated plasma prolactin levels were observed in 26% of adults treated with FANAPT compared to 12% in the placebo-group.Â In the short-term trials, FANAPT was associated with modest levels of prolactin elevation compared to greater prolactin elevations observed with some other antipsychotic agents.Â In pooled analysis from clinical studies including longer term trials, in 3210 adults treated with iloperidone, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> was reported in 2 male subjects (0.1%) compared to 0% in placebo-treated patients, and <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span> was reported in 8 female subjects (0.2%) compared to 3 female subjects (0.5%) in placebo-treated patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p10"></a><a name="section-5.10"></a><p></p>
<h2>5.10Â Â Â Â Â Body Temperature Regulation</h2>
<p class="First">Disruption of the bodyâ€™s ability to reduce core body temperature has been attributed to antipsychotic agents.Â Appropriate care is advised when prescribing FANAPT for patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p11"></a><a name="section-5.11"></a><p></p>
<h2>5.11Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></h2>
<p class="First">Esophageal dysmotility and <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> have been associated with antipsychotic drug use. <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">Aspiration pneumonia</span> is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimerâ€™s <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. FANAPT and other antipsychotic drugs should be used cautiously in patients at risk for <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">aspiration pneumonia</span> <span class="Italics">[see Boxed Warning]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p12"></a><a name="section-5.12"></a><p></p>
<h2>5.12Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span></h2>
<p class="First">The possibility of a <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> is inherent in <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> illness, and close supervision of high-risk patients should accompany drug therapy. Prescriptions for FANAPT should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p13"></a><a name="section-5.13"></a><p></p>
<h2>5.13Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span></h2>
<p class="First">Three cases of <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span> were reported in the premarketing FANAPTÂ program.Â Drugs with alpha-adrenergic blocking effects have been reported to induce <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>.Â FANAPT shares this pharmacologic activity. Severe <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span> may require <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5p14"></a><a name="section-5.14"></a><p></p>
<h2>5.14Â Â Â Â Â Potential for Cognitive and Motor Impairment</h2>
<p class="First">FANAPT, like other antipsychotics, has the potential to impair judgment, thinking or motor skills.Â In short-term, placebo-controlled trials, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (including sedation) was reported in 11.9% (104/874) of adult patients treated with FANAPT<span class="Sup">Â </span>at doses of 10 mg/day or greater versus 5.3% (31/587) treated with placebo.Â Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that therapy with FANAPT does not affect them adversely.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>6Â Â Â Â Â ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s6p1"></a><a name="section-6.1"></a><p></p>
<h2>6.1Â Â Â Â Â Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The information below is derived from a clinical trial database for FANAPT consisting of 2070 patients exposed to FANAPT at doses of 10 mg/day or greater, for the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. Of these, 806 received FANAPT for at least 6 months, with 463 exposed to FANAPT for at least 12 months. All of these patients who received FANAPT were participating in multiple-dose clinical trials. The conditions and duration of treatment with FANAPT varied greatly and included (in overlapping categories), open-label and double-blind phases of studies, inpatients and outpatients, fixed-dose and flexible-dose studies, and short-term and longer-term exposure.</p>
<p>Adverse reactions during exposure were obtained by general inquiry and recorded by clinical investigators using their own terminology.Â Consequently, to provide a meaningful estimate of the proportion of individuals experiencing adverse reactions, reactions were grouped in standardized categories using MedDRA terminology.</p>
<p>The stated frequencies of adverse reactions represent the proportions of individuals who experienced a treatment-emergent adverse reaction of the type listed.Â A reaction was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.</p>
<p>The information presented in these sections was derived from pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies in patients who received FANAPT at daily doses within a range of 10 to 24 mg (n=874).Â </p>
<p><span class="Bold">Adverse Reactions Occurring at an Incidence of 2% or More among </span><span class="Bold">FANAPT</span><span class="Bold">-Treated Patients</span><span class="Bold">Â </span><span class="Bold">and More </span><span class="Bold">Frequent than Placebo</span></p>
<p>Table 7 enumerates the pooled incidences of treatment-emergent adverse reactions that were spontaneously reported in four placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, listing those reactions that occurred in 2% or more of patients treated with FANAPT in any of the dose groups, and for which the incidence in FANAPT-treated patients in any dose group was greater than the incidence in patients treated with placebo.Â </p>
<table>
<caption><span>Table 7: Percentage of Treatment-Emergent Adverse Reactions in Short-Term, Fixed- or Flexible-Dose, Placebo-Controlled Trials in Adult Patients*</span></caption>
<col width="323">
<col width="195">
<col width="231">
<col width="231">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold">Body System or Organ Class</span></td>
<td align="center"><span class="Bold">Placebo<br>(%)</span></td>
<td align="center"><span class="Bold">FANAPT 10-16 mg/day<br>(%)</span></td>
<td align="center"><span class="Bold">FANAPT 20-24 mg/day<br>(%)</span></td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	Dictionary-derived Term</td>
<td align="center"><span class="Bold">(N=587)</span></td>
<td align="center"><span class="Bold">(N=483)</span></td>
<td align="center"><span class="Bold">(N=391)</span></td>
</tr>
<tr>
<td class="Toprule"><span class="Bold">Body as a Whole</span></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">3</td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">6</td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">Musculoskeletal Stiffness</span></td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">3</td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Increased</span></td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">9</td>
</tr>
<tr>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">12</td>
</tr>
<tr>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision Blurred</span></td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">1</td>
</tr>
<tr>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">8</td>
<td align="center">7</td>
<td align="center">10</td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td align="center">1</td>
<td align="center">8</td>
<td align="center">10</td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">4</td>
<td align="center">5</td>
<td align="center">7</td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal Discomfort</span></td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">3</td>
</tr>
<tr>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">3</td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">3</td>
</tr>
<tr>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">7</td>
<td align="center">10</td>
<td align="center">20</td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">5</td>
<td align="center">9</td>
<td align="center">15</td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Disorder</span></td>
<td align="center">4</td>
<td align="center">5</td>
<td align="center">4</td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">3</td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">1</td>
</tr>
<tr>
<td><span class="Bold">Reproductive System</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="4088757" conceptname="Anejaculation">Ejaculation Failure</span></td>
<td align="center">&lt;1</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
<tr>
<td><span class="Bold">Respiratory</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal Congestion</span></td>
<td align="center">2</td>
<td align="center">5</td>
<td align="center">8</td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td align="center">&lt;1</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
<tr>
<td><span class="Bold">Skin</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">2</td>
</tr>
<tr>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">5</td>
</tr>
<tr class="Last">
<td>
		Â Â Â Â Â 
	<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td align="center">&lt;1</td>
<td align="center">&lt;1</td>
<td align="center">3</td>
</tr>
</tbody>
</table>
<p>* Table includes adverse reactions that were reported in 2% or more of patients in any of the FANAPT dose groups and which occurred at greater incidence than in the placebo-group.Â Figures rounded to the nearest integer.Â </p>
<p><span class="Bold">Dose-Related Adverse Reactions in Clinical Trials</span></p>
<p>Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, adverse reactions that occurred with a greater than 2% incidence in the patients treated with FANAPT, and for which the incidence in patients treated withÂ FANAPT<span class="Sup">Â </span>20 to 24 mg/day were twice than the incidence in patients treated withÂ FANAPTÂ 10 to 16 mg/day were: <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">musculoskeletal stiffness</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span>.Â </p>
<p><span class="Bold">Common and Drug-Related Adverse Reactions in Clinical Trials</span></p>
<p>Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, the following adverse reactions occurred in â‰¥5% incidence in the patients treated with FANAPT and at least twice the placebo rate for at least 1 dose: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span>. <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span> were at least twice as common on 20 to 24 mg/day as on 10 to 16 mg/day.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span> (EPS) in Clinical Trials</span></p>
<p>Pooled data from the 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies provided information regarding treatment-emergent EPS. Adverse event data collected from those trials showed the following rates of EPS-related adverse events as shown in Table 8.</p>
<table>
<caption><span>Table 8:Â Percentage of EPS Compared to Placebo</span></caption>
<col width="245">
<col width="245">
<col width="245">
<col width="245">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Toprule" align="center"><span class="Bold">Placebo<br>(%)</span></td>
<td class="Toprule" align="center"><span class="Bold">FANAPT 10-16 mg/day<br>(%)</span></td>
<td class="Toprule" align="center"><span class="Bold">FANAPT 20-24 mg/day<br>(%)</span></td>
</tr>
<tr>
<td><span class="Bold">Adverse Event Term</span></td>
<td align="center"><span class="Bold">(N=587)</span></td>
<td align="center"><span class="Bold">(N=483)</span></td>
<td align="center"><span class="Bold">(N=391)</span></td>
</tr>
<tr>
<td class="Toprule"><span class="Bold">All EPS events</span></td>
<td class="Toprule" align="center"><span class="Bold">11.6</span></td>
<td class="Toprule" align="center"><span class="Bold">13.5</span></td>
<td class="Toprule" align="center"><span class="Bold">15.1</span></td>
</tr>
<tr>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span></td>
<td class="Toprule" align="center">2.7</td>
<td class="Toprule" align="center">1.7</td>
<td class="Toprule" align="center">2.3</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">Bradykinesia</span></td>
<td align="center">0</td>
<td align="center">0.6</td>
<td align="center">0.5</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span></td>
<td align="center">1.5</td>
<td align="center">1.7</td>
<td align="center">1.0</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span></td>
<td align="center">0.7</td>
<td align="center">1.0</td>
<td align="center">0.8</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span></td>
<td align="center">0</td>
<td align="center">0.2</td>
<td align="center">0.3</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td align="center">1.9</td>
<td align="center">2.5</td>
<td align="center">3.1</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Adverse Reactions Associated with Discontinuation of Treatment in Clinical Trials</span></p>
<p>Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, there was no difference in the incidence of discontinuation due to adverse events between FANAPT-treated (5%) and placebo-treated (5%) patients.Â The types of adverse events that led to discontinuation were similar for the FANAPT- and placebo-treated patients.</p>
<p><span class="Bold">Demographic Differences in Adverse Reactions in Clinical Trials</span></p>
<p>An examination of population subgroups in the 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies did not reveal any evidence of differences in safety on the basis of age, gender or race <span class="Italics">[see Warnings and Precautions (5.1)]</span>.</p>
<p><span class="Bold">Laboratory Test Abnormalities in Clinical Trials</span></p>
<p>There were no differences between FANAPT and placebo in the incidence of discontinuation due to changes in hematology, urinalysis, or serum chemistry.</p>
<p>In short-term placebo-controlled trials (4- to 6-weeks), there were 1.0% (13/1342) iloperidone-treated patients with hematocrit at least one time below the extended normal range during post-randomization treatment, compared to 0.3% (2/585) on placebo.Â The extended normal range for lowered hematocrit was defined in each of these trials as the value 15% below the normal range for the centralized laboratory that was used in the trial.Â </p>
<p><span class="Bold">Other Reactions During the Premarketing Evaluation of FANAPT</span></p>
<p>The following is a list of MedDRA terms that reflect treatment-emergent adverse reactions in patients treated with FANAPT at multiple doses â‰¥4 mg/day during any phase of a trial with the database of 3210 FANAPT-treated patients.Â All reported reactions are included except those already listed in Table 7, or other parts of the <span class="Italics">Adverse Reactions (6)</span> section, those considered in the <span class="Italics">Warnings and Precautions (5)</span>, those reaction terms which were so general as to be uninformative, reactions reported in fewer than 3 patients and which were neither serious nor life-threatening, reactions that are otherwise common as background reactions, and reactions considered unlikely to be drug related.Â It is important to emphasize that, although the reactions reported occurred during treatment with FANAPT, they were not necessarily caused by it.</p>
<p>Reactions are further categorized by MedDRA system organ class and listed in order of decreasing frequency according to the following definitions: frequent adverse events are those occurring in at least 1/100 patients (only those not listed in Table 7 appear in this listing); infrequent adverse reactions are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients.</p>
<p><span class="Italics">Blood and Lymphatic Disorders: Infrequent</span> â€“ <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span>; <span class="Italics">Rare</span> â€“ <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>: Frequent â€“ </span><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>;<span class="Italics"> Rare</span> â€“ <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="314379" conceptname="First degree atrioventricular block">atrioventricular block first degree</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> (including congestive and acute)</p>
<p><span class="Italics">Ear and Labyrinth Disorders: Infrequent â€“</span>Â <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span>: Infrequent</span> â€“ <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>: Frequent -</span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> (including allergic); <span class="Italics">Infrequent</span> â€“Â <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span>, <span class="product-label-link" type="condition" conceptid="374950" conceptname="Edema of eyelid">eyelid edema</span>, <span class="product-label-link" type="condition" conceptid="381299" conceptname="Swelling of structure of eye">eye swelling</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">lenticular opacities</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>, <span class="product-label-link" type="condition" conceptid="4146766" conceptname="Hyperemia">hyperemia</span> (including conjunctival) </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>: Infrequent</span> â€“Â <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivary hypersecretion</span>,Â <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>;Â <span class="Italics">Rare</span>Â -Â <span class="product-label-link" type="condition" conceptid="138463" conceptname="Aphthous ulcer of mouth">aphthous stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, <span class="product-label-link" type="condition" conceptid="4224004" conceptname="Hiatal hernia">hiatus hernia</span>, <span class="product-label-link" type="condition" conceptid="4265627" conceptname="Hyperchlorhydria">hyperchlorhydria</span>, <span class="product-label-link" type="condition" conceptid="4271702" conceptname="Lip ulcer">lip ulceration</span>, <span class="product-label-link" type="condition" conceptid="30437" conceptname="Gastro-esophageal reflux disease with esophagitis">reflux esophagitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span></p>
<p><span class="Italics">General Disorders and Administrative Site Conditions: Infrequent</span> â€“ <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (general, pitting, due to cardiac disease), <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">difficulty in walking</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>; <span class="Italics">Rare</span> - <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span></p>
<p><span class="Italics">Hepatobiliary Disorders: Infrequent â€“ </span><span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span></p>
<p><span class="Italics">Investigations: Frequent - </span><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreased</span>; <span class="Italics">Infrequent</span> â€“Â <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">hemoglobin decreased</span>, neutrophil count increased, <span class="product-label-link" type="condition" conceptid="4216894" conceptname="Precipitous drop in hematocrit">hematocrit decreased</span></p>
<p><span class="Italics">Metabolism and Nutrition Disorders:</span>Â <span class="Italics">Infrequent</span> â€“ <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span></p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>: Frequent</span> â€“Â <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>; <span class="Italics">Rare</span> â€“ <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:Â InfrequentÂ â€“</span>Â <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">psychomotor hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>; <span class="Italics">Rare</span> â€“Â <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">restless legs syndrome</span></p>
<p><span class="Italics">Psychiatric Disorders: Frequent</span> â€“ <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusion</span>; <span class="Italics">Infrequent</span> â€“ <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">libido decreased</span>, <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>, <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">anorgasmia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attack</span>, obsessive-compulsive disorder, <span class="product-label-link" type="condition" conceptid="438407" conceptname="Bulimia nervosa">bulimia nervosa</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4049477" conceptname="Psychogenic polydipsia">polydipsia psychogenic</span>, <span class="product-label-link" type="condition" conceptid="433752" conceptname="Impulse control disorder">impulse-control disorder</span>, <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span></p>
<p><span class="Italics">Renal and Urinary Disorders: Frequent</span> â€“ <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>; <span class="Italics">Infrequent</span> â€“ <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">pollakiuria</span>, <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">enuresis</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span>; <span class="Italics">Rare</span> â€“ <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">renal failure acute</span></p>
<p><span class="Italics">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span>: Frequent</span> â€“ <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>; <span class="Italics">Infrequent</span> â€“ <span class="product-label-link" type="condition" conceptid="4270932" conceptname="Pain in testicle">testicular pain</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>;Â <span class="Italics">Rare</span> â€“ <span class="product-label-link" type="condition" conceptid="196168" conceptname="Irregular periods">menstruation irregular</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>, <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span>, <span class="product-label-link" type="condition" conceptid="195321" conceptname="Postmenopausal bleeding">postmenopausal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">prostatitis</span>.</p>
<p><span class="Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>: Infrequent</span> â€“ <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4220211" conceptname="Congestion of nasal sinus">sinus congestion</span>, <span class="product-label-link" type="condition" conceptid="4171214" conceptname="Nasal mucosa dry">nasal dryness</span>; <span class="Italics">Rare</span> â€“ <span class="product-label-link" type="condition" conceptid="4010026" conceptname="Pharyngeal dryness">dry throat</span>, <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea syndrome</span>, <span class="product-label-link" type="condition" conceptid="4263848" conceptname="Dyspnea on exertion">dyspnea exertional</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6p2"></a><a name="section-6.2"></a><p></p>
<h2>6.2Â Â Â Â Â Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of FANAPT: <span class="product-label-link" type="condition" conceptid="435866" conceptname="Retrograde ejaculation">retrograde ejaculation</span>. Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s7"></a><a name="section-7"></a><p></p>
<h1>7Â Â Â Â Â DRUG INTERACTIONS</h1>
<p class="First">Given the primary CNS effects of FANAPT, caution should be used when it is taken in combination with other centrally acting drugs and alcohol. Due to its alpha1-adrenergic receptor antagonism, FANAPT has the potential to enhance the effect of certain antihypertensive agents.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s7p1"></a><a name="section-7.1"></a><p></p>
<h2>7.1Â Â Â Â Â Potential for Other Drugs to Affect FANAPT</h2>
<p class="First">Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes.Â This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.</p>
<p>Both CYP3A4 and CYP2D6 are responsible for iloperidone metabolism.Â Inhibitors of CYP3A4 (e.g., ketoconazole) or CYP2D6 (e.g., fluoxetine, paroxetine) can inhibit iloperidone elimination and cause increased blood levels.Â </p>
<p><span class="Bold Italics">Ketoconazole:</span> Co-administration of ketoconazole (200 mg twice daily for 4 days), a potent inhibitor of CYP3A4, with a 3 mg single dose of iloperidone to 19 healthy volunteers, ages 18 to 45 years, increased the area under the curve (AUC) of iloperidone and its metabolites P88 and P95 by 57%, 55% and 35%, respectively. Iloperidone doses should be reduced by about one-half when administered with ketoconazole or other strong inhibitors of CYP3A4 (e.g., itraconazole). Weaker inhibitors (e.g., erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.</p>
<p><span class="Bold Italics">Fluoxetine</span>: Co-administration of fluoxetine (20 mg twice daily for 21 days), a potent inhibitor of CYP2D6, with a single 3 mg dose of iloperidone to 23 healthy volunteers, ages 29 to 44 years, who were classified as CYP2D6 extensive metabolizers, increased the AUC of iloperidone and its metabolite P88, by about 2- to 3-fold, and decreased the AUC of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with fluoxetine. When fluoxetine is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level. Other strong inhibitors of CYP2D6 would be expected to have similar effects and would need appropriate dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, iloperidone dose could then be increased to the previous level.</p>
<p><span class="Bold Italics">Paroxetine:</span> Co-administration of paroxetine (20 mg/day for 5 to 8 days), a potent inhibitor of CYP2D6, with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> ages 18 to 65 years resulted in increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by about 1.6-fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half. Iloperidone doses should be reduced by one-half when administered with paroxetine. When paroxetine is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level. Other strong inhibitors of CYP2D6 would be expected to have similar effects and would need appropriate dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, iloperidone dose could then be increased to previous levels.</p>
<p><span class="Bold Italics">Paroxetine and Ketoconazole:</span><span class="Bold">Â </span>Co-administration of paroxetine (20 mg once daily for 10 days), a CYP2D6 inhibitor, and ketoconazole (200 mg twice daily) with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> ages 18 to 65 years resulted in a 1.4-fold increase in steady-state concentrations of iloperidone and its metabolite P88 and a 1.4-fold decrease in the P95 in the presence of paroxetine. So giving iloperidone with inhibitors of both of its metabolic pathways did not add to the effect of either inhibitor given alone. Iloperidone doses should therefore be reduced by about one-half if administered concomitantly with both a CYP2D6 and CYP3A4 inhibitor.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7p2"></a><a name="section-7.2"></a><p></p>
<h2>7.2Â Â Â Â Â Potential for FANAPT to Affect Other Drugs</h2>
<p class="First"><span class="Italics">In vitro</span> studies in human liver microsomes showed that iloperidone does not substantially inhibit the metabolism of drugs metabolized by the following cytochrome P450 isozymes: CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, or CYP2E1. Furthermore, <span class="Italics">in vitro</span> studies in human liver microsomes showed that iloperidone does not have enzyme inducing properties, specifically for the following cytochrome P450 isozymes: CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP3A4 and CYP3A5.</p>
<p><span class="Bold Italics">Dextromethorphan:</span> A study in healthy volunteers showed that changes in the pharmacokinetics of dextromethorphan (80 mg dose) when a 3 mg dose of iloperidone was co-administered resulted in a 17% increase in total exposure and a 26% increase in the maximum plasma concentrations (C<span class="Sub">max</span>)of dextromethorphan. Thus, an interaction between iloperidone and other CYP2D6 substrates is unlikely.</p>
<p><span class="Bold Italics">Fluoxetine:</span>Â A single 3 mg dose of iloperidone had no effect on the pharmacokinetics of fluoxetine (20Â mg twice daily).Â </p>
<p><span class="Bold Italics">Midazolam (a sensitive CYP 3A4 substrate):</span>Â A study in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> showed a less than 50% increase in midazolam total exposure at iloperidone steady state (14 days of oral dosing at up to 10 mg iloperidone twice daily) and no effect on midazolam C<span class="Sub">max</span>. Thus, an interaction between iloperidone and other CYP3A4 substrates is unlikely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7p3"></a><a name="section-7.3"></a><p></p>
<h2>7.3Â Â Â Â Â Drugs that Prolong the QT Interval</h2>
<p class="First">FANAPT should not be used with any other drugs that prolong the QT interval <span class="Italics">[see Warnings and Precautions (5.2)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s8"></a><a name="section-8"></a><p></p>
<h1>8Â Â Â Â Â USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s8p1"></a><a name="section-8.1"></a><p></p>
<h2>8.1Â Â Â Â Â Pregnancy</h2>
<p class="First">Pregnancy Category C</p>
<p>FANAPT caused developmental toxicity, but was notÂ teratogenic, in rats and rabbits.</p>
<p>In an embryo-fetal development study, pregnant rats were given 4, 16, or 64 mg/kg/day (1.6, 6.5, and 26 times the maximum recommended human dose (MRHD) of 24 mg/day on a mg/m<span class="Sup">2</span> basis) of iloperidone orally during the period of organogenesis.Â The highest dose caused increased early intrauterine <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, decreased fetal weight and length, decreased fetal skeletal ossification, and an increased incidence of minor fetal skeletal anomalies and variations; this dose also caused decreased maternal food consumption and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</p>
<p>In an embryo-fetal development study, pregnant rabbits were given 4, 10, or 25 mg/kg/day (3, 8, and 20 times the MRHD on a mg/m<span class="Sup">2</span> basis) of iloperidone during the period of organogenesis.Â The highest dose caused increased early intrauterine <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> and decreased fetal viability at term; this dose also caused maternal toxicity.Â </p>
<p>In additional studies in which rats were given iloperidone at doses similar to the above beginning from either pre-conception or from day 17 of gestation and continuing through weaning, adverse reproductive effects included <span class="product-label-link" type="condition" conceptid="432695" conceptname="Post-term pregnancy">prolonged pregnancy</span> and parturition, increased <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirth</span> rates, increased incidence of fetal visceral variations, decreased fetal and pup weights, and decreased post-partum pup survival. There were no drug effects on the neurobehavioral or reproductive development of the surviving pups. No-effect doses ranged from 4 to 12 mg/kg except for the increase in <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirth</span> rates which occurred at the lowest dose tested of 4 mg/kg, which is 1.6 times the MRHD on a mg/m<span class="Sup">2 </span>basis. Maternal toxicity was seen at the higher doses in these studies. </p>
<p>The iloperidone metabolite P95, which is a major circulating metabolite of iloperidone in humans but is not present in significant amounts in rats, was given to pregnant rats during the period of organogenesis at oral doses of 20, 80, or 200 mg/kg/day. No teratogenic effects were seen. Delayed skeletal ossification occurred at all doses. No significant maternal toxicity was produced. Plasma levels of P95 (AUC) at the highest dose tested were 2 times those in humans receiving the MRHD of iloperidone.</p>
<p>There are no adequate and well-controlled studies in pregnant women.</p>
<p>Non-teratogenic Effects</p>
<p>Neonates exposed to antipsychotic drugs, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> and <span class="product-label-link" type="condition" conceptid="434750" conceptname="Feeding difficulties and mismanagement">feeding disorder</span> in these neonates.Â These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization.</p>
<p>FANAPT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s8p2"></a><a name="section-8.2"></a><p></p>
<h2>8.2Â Â Â Â Â Labor and Delivery</h2>
<p class="First">The effect of FANAPT on labor and delivery in humans is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s8p3"></a><a name="section-8.3"></a><p></p>
<h2>8.3Â Â Â Â Â Nursing Mothers</h2>
<p class="First">FANAPT was excreted in milk of rats during lactation.Â It is not known whether FANAPT or its metabolites are excreted in human milk.Â It is recommended that women receiving FANAPT should not breastfeed.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s8p4"></a><a name="section-8.4"></a><p></p>
<h2>8.4Â Â Â Â Â Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric and adolescent patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s8p5"></a><a name="section-8.5"></a><p></p>
<h2>8.5Â Â Â Â Â Geriatric Use</h2>
<p class="First">Clinical Studies of FANAPT in the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> did not include sufficient numbers of patients aged 65 years and over to determine whether or not they respond differently than younger adult patients.Â Of the 3210 patients treated with FANAPT in premarketing trials, 25 (0.5%) were â‰¥65 years old and there were no patients â‰¥75 years old. </p>
<p>Studies of elderly patients with <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> associated with Alzheimerâ€™s disease have suggested that there may be a different tolerability profile (i.e., increased risk in mortality and cerebrovascular events including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>) in this population compared to younger patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> <span class="Italics">[see Boxed Warning and Warnings and Precautions (5.1)]</span>.Â The safety and efficacy of FANAPT in the treatment of patients with <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> associated with Alzheimerâ€™s disease has not been established.Â If the prescriber elects to treat such patients with FANAPT, vigilance should be exercised.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8p6"></a><a name="section-8.6"></a><p></p>
<h2>8.6Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Because FANAPT is highly metabolized, with less than 1% of the drug excreted unchanged, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> alone is unlikely to have a significant impact on the pharmacokinetics of FANAPT.Â <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> (creatinine clearance &lt;30 mL/min) had minimal effect on C<span class="Sub">max</span> of iloperidone (given in a single dose of 3 mg) and its metabolites P88 and P95 in any of the 3 analytes measured.Â AUC<span class="Sub">0â€“âˆž </span>was increased by 24%, decreased by 6%, and increased by 52% for iloperidone, P88 and P95, respectively, in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8p7"></a><a name="section-8.7"></a><p></p>
<h2>8.7Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No dose adjustment to FANAPT is needed in patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Exercise caution when administering it to patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. FANAPT is not recommended for patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Dosage in Special Populations (2.2)]</span>.</p>
<p>In adult subjects with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> no relevant difference in pharmacokinetics of iloperidone, P88 or P95 (total or unbound) was observed compared to healthy adult controls. In subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> a higher (2-fold) and more variable free exposure to the active metabolites P88 was observed compared to healthy controls, whereas exposure to iloperidone and P95 was generally similar (less than 50% change compared to control). Since a study in severe liver impaired subjects has not been conducted, FANAPT is not recommended for patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8p8"></a><a name="section-8.8"></a><p></p>
<h2>8.8Â Â Â Â Â Smoking Status</h2>
<p class="First">Based on <span class="Italics">in vitro</span> studies utilizing human liver enzymes, FANAPT is not a substrate for CYP1A2; smoking should therefore not have an effect on the pharmacokinetics of FANAPT.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<h1>9Â Â Â Â Â DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="section-9.1"></a><p></p>
<h2>9.1Â Â Â Â Â Controlled Substance</h2>
<p class="First">FANAPT is not a controlled substance.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="section-9.2"></a><p></p>
<h2>9.2Â Â Â Â Â Abuse</h2>
<p class="First">FANAPT has not been systematically studied in animals or humans for its potential for abuse, tolerance, or physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.Â While the clinical trials did not reveal any tendency for drug-seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this experience the extent to which a CNS active drug,Â FANAPT, will be misused, diverted, and/or abused once marketed.Â Consequently, patients should be evaluated carefully for a history of drug abuse, and such patients should be observed closely for signs of FANAPT misuse or abuse (e.g., development of tolerance, increases in dose, drug-seeking behavior).</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>10Â Â Â Â Â OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>10.1Â Â Â Â Â Human Experience</h2>
<p class="First">In premarketing trials involving over 3210 patients, accidental or <span class="product-label-link" type="condition" conceptid="4244894" conceptname="Intentional drug overdose">intentional overdose</span> of FANAPT was documented in 8 patients ranging from 48 mg to 576 mg taken at once and 292 mg taken over a 3-day period.Â No fatalities were reported from these cases.Â The largest confirmed single ingestion of FANAPT was 576 mg; no adverse physical effects were noted for this patient.Â The next largest confirmed ingestion of FANAPT was 438 mg over a 4-day period; <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> and a QTc interval of 507 msec were reported for this patient with no cardiac sequelae.Â This patient resumed FANAPT treatment for an additional 11 months.Â In general, reported signs and symptoms were those resulting from an exaggeration of the known pharmacological effects (e.g., <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and sedation, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>) of FANAPT.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>10.2Â Â Â Â Â Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></h2>
<p class="First">There is no specific antidote for FANAPT. Therefore appropriate supportive measures should be instituted. In case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span>, the physician should establish and maintain an airway and ensure adequate oxygenation and ventilation. Gastric lavage (after intubation, if patient is <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span>) and administration of activated charcoal together with a laxative should be considered. The possibility of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">obtundation</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reaction</span> of the head and neck following <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may create a risk of <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> with induced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>. Cardiovascular monitoring should commence immediately and should include continuous ECG monitoring to detect possible <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>. If antiarrhythmic therapy is administered, disopyramide, procainamide and quinidine should not be used, as they have the potential for QT-prolonging effects that might be additive to those of FANAPT. Similarly, it is reasonable to expect that the alpha-blocking properties of bretylium might be additive to those of FANAPT, resulting in problematic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> should be treated with appropriate measures such as intravenous fluids or sympathomimetic agents (epinephrine and dopamine should not be used, since beta stimulation may worsen <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in the setting of FANAPT-induced alpha blockade). In cases of severe <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, anticholinergic medication should be administered. Close medical supervision should continue until the patient recovers.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-11"></a><p></p>
<h1>11Â Â Â Â Â DESCRIPTION</h1>
<p class="First">FANAPT is a psychotropic agent belonging to the chemical class of piperidinyl-benzisoxazole derivatives.Â Its chemical name is 4â€™-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino]propoxy]-3â€™-methoxyacetophenone.Â Its molecular formula is C<span class="Sub">24</span>H<span class="Sub">27</span>FN<span class="Sub">2</span>O<span class="Sub">4</span> and its molecular weight is 426.48.Â The structural formula is:</p>
<p><img alt="FANAPT structural formula " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=43452bf8-76e7-47a9-a5d8-41fe84d061f0&amp;name=fanapt-02.jpg"></p>
<p>Iloperidone is a white to off-white finely crystalline powder.Â It is practically insoluble in water, very slightly soluble in 0.1 N HCl and freely soluble in chloroform, ethanol, methanol, and acetonitrile.</p>
<p>FANAPT tablets are intended for oral administration only.Â Each round, uncoated tablet contains 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, or 12 mg of iloperidone.Â Inactive ingredients are: lactose monohydrate, microcrystalline cellulose, hydroxypropylmethylcellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and purified water (removed during processing). The tablets are white, round, flat, beveled-edged and identified with a logo â€œ<img alt="Tablet Imprint " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=43452bf8-76e7-47a9-a5d8-41fe84d061f0&amp;name=fanapt-01.jpg">â€? debossed on one side and tablet strength â€œ1â€?, â€œ2â€?, â€œ4â€?, â€œ6â€?, â€œ8â€?, â€œ10â€?, or â€œ12â€? debossed on the other side.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-12"></a><p></p>
<h1>12Â Â Â Â Â CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-12.1"></a><p></p>
<h2>12.1Â Â Â Â Â Mechanism of Action</h2>
<p class="First">The mechanism of action of FANAPT, as with other drugs having efficacy in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, is unknown.Â However it is proposed that the efficacy of FANAPTÂ is mediated through a combination of dopamine type 2 (D<span class="Sub">2</span>) and serotonin type 2 (5-HT<span class="Sub">2</span>) antagonisms.Â </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-12.2"></a><p></p>
<h2>12.2Â Â Â Â Â Pharmacodynamics</h2>
<p class="First">FANAPT exhibits high (nM) affinity binding to serotonin 5-HT<span class="Sub">2A</span> dopamine D<span class="Sub">2</span> and D<span class="Sub">3</span> receptors, and norepinephrine NEÎ±1 receptors (K<span class="Sub">i</span> values of 5.6, 6.3, 7.1, and 0.36 nM, respectively).  FANAPT has moderate affinity for dopamine D<span class="Sub">4</span>, and serotonin 5-HT<span class="Sub">6</span> and 5-HT<span class="Sub">7</span> receptors (K<span class="Sub">i</span> values of 25, 43, and 22, nM respectively), and low affinity for the serotonin 5-HT<span class="Sub">1A</span>, dopamine D<span class="Sub">1</span>, and histamine H<span class="Sub">1</span> receptors (K<span class="Sub">i</span> values of 168, 216 and 437 nM, respectively). FANAPT has no appreciable affinity (K<span class="Sub">i</span> &gt;1000 nM) for cholinergic muscarinic receptors. FANAPT functions as an antagonist at the dopamine D<span class="Sub">2</span>, D<span class="Sub">3</span>, serotonin 5-HT<span class="Sub">1A</span> and norepinephrine Î±<span class="Sub">1</span>/Î±<span class="Sub">2C</span> receptors.Â The affinity of the FANAPT metabolite P88 is generally equal or less than that of the parent compound.Â In contrast, the metabolite P95 only shows affinity for 5-HT<span class="Sub">2A</span> (K<span class="Sub">i</span> value of 3.91) and the NE<span class="Sub">Î±1A</span>, NE<span class="Sub">Î±1B</span>, NE<span class="Sub">Î±1D</span>, and NE<span class="Sub">Î±2</span><span class="Sub">C</span> receptors (K<span class="Sub">i</span> values of 4.7, 2.7, 8.8, and 4.7 nM respectively).Â </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s12p3"></a><a name="section-12.3"></a><p></p>
<h2>12.3Â Â Â Â Â Pharmacokinetics</h2>
<p class="First">The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM)Â are 18, 26, and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37, and 31 hours, respectively.Â Steady-state concentrations are attained withinÂ 3 to 4 days of dosing. Iloperidone accumulation is predictable from single-dose pharmacokinetics.Â The pharmacokinetics of iloperidone is more than dose proportional. Elimination of iloperidone is mainly through hepatic metabolism involving 2 P450 isozymes, CYP2D6 and CYP3A4.</p>
<p><span class="Bold Italics">Absorption:</span>Â Iloperidone is well absorbed after administration of the tablet with peak plasma concentrations occurring within 2 to 4 hours; while the relative bioavailability of the tablet formulation compared to oral solution is 96%.Â Administration of iloperidone with a standard high-fat meal did not significantly affect the C<span class="Sub">max</span> or AUC of iloperidone, P88, or P95, but delayed T<span class="Sub">max</span> by 1 hour for iloperidone, 2 hours for P88 and 6 hours for P95. FANAPT can be administered without regard to meals.Â </p>
<p><span class="Bold Italics">Distribution:</span>Â Iloperidone has an apparent clearance (clearance/bioavailability) of 47 to 102 L/h, with an apparent volume of distribution of 1340 to 2800 L. At therapeutic concentrations, the unbound fraction of iloperidone in plasma is ~3% and of each metabolite (P88 and P95) it is ~8%.</p>
<p><span class="Bold Italics">Metabolism and Elimination:</span><span class="Bold">Â </span>Iloperidone is metabolized primarily by 3 biotransformation pathways: carbonyl reduction, hydroxylation (mediated by CYP2D6) and <span class="Italics">O</span>-demethylation (mediated by CYP3A4). There are 2 predominant iloperidone metabolites, P95 and P88. The iloperidone metabolite P95 represents 47.9% of the AUC of iloperidone and its metabolites in plasma at steady-state for extensive metabolizers (EM) and 25% for poor metabolizers (PM). The active metabolite P88 accounts for 19.5% and 34.0% of total plasma exposure in EM and PM, respectively.</p>
<p>Approximately 7% to 10% of Caucasians and 3% to 8% of black/African Americans lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are intermediate, extensive or ultrarapid metabolizers.Â Co-administration of FANAPT with known strong inhibitors of CYP2D6 like fluoxetine results in a 2.3-fold increase in iloperidone plasma exposure, andÂ therefore one-half of the FANAPT dose should be administered. </p>
<p>Similarly, PMs of CYP2D6 have higher exposure to iloperidone compared with EMsÂ and PMs should have their dose reduced by one-half.Â Laboratory tests are available to identify CYP2D6 PMs.</p>
<p>The bulk of the radioactive materials were recovered in the urine (mean 58.2% and 45.1% in EM and PM, respectively), with feces accounting for 19.9% (EM) to 22.1% (PM) of the dosed radioactivity.</p>
<p><span class="Bold Italics">Transporter Interaction: </span>Iloperidone and P88 are not substrates of P-gp and iloperidone is a weak P-gp inhibitor.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-13"></a><p></p>
<h1>13Â Â Â Â Â NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-13.1"></a><p></p>
<h2>13.1Â Â Â Â Â Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Bold Italics">Carcinogenesis:</span>Â Lifetime carcinogenicity studies were conducted in CD-1 mice and Sprague Dawley rats. Iloperidone was administered orally at doses of 2.5, 5.0, and 10 mg/kg/day to CD-1 mice and 4, 8, and 16 mg/kg/day to Sprague Dawley rats (0.5, 1.0, and 2.0 times and 1.6, 3.2, and 6.5 times, respectively, the MRHD of 24 mg/day on a mg/m<span class="Sup">2</span> basis). There was an increased incidence of malignant mammary gland tumors in female mice treated with the lowest dose (2.5 mg/kg/day) only. There were no treatment-related increases in neoplasia in rats.</p>
<p>The carcinogenic potential of the iloperidone metabolite P95, which is a major circulating metabolite of iloperidone in humans but is not present at significant amounts in mice or rats, was assessed in a lifetime carcinogenicity study in Wistar rats at oral doses of 25, 75, and 200 mg/kg/day in males and 50, 150, and 250 (reduced from 400) mg/kg/day in females. </p>
<p>Drug-related neoplastic changes occurred in males, in the pituitary gland (pars distalis <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span>) at all doses and in the pancreas (islet cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span>) at the high dose. Plasma levels of P95 (AUC) in males at the tested doses (25, 75, and 200 mg/kg/day) were approximately 0.4, 3, and 23 times, respectively, the human exposure to P95 at the MRHD of iloperidone.</p>
<p>An increase in mammary, pituitary and endocrine pancreas neoplasms has been found in rodents after chronic administration of other antipsychotic drugs and is considered to be mediated by prolonged dopamine D2 antagonism and <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span>. Increases in serum prolactin were seen in mice and rats treated with iloperidone. The relevance of these tumor findings in rodents in terms of human risk is unknown.</p>
<p><span class="Bold Italics">Mutagenesis:</span>Â Iloperidone was negative in the Ames test and in the <span class="Italics">in vivo</span> mouse bone marrow and rat liver micronucleus tests. IloperidoneÂ induced chromosomal aberrations in Chinese Hamster Ovary (CHO) cells <span class="Italics">in vitro</span> at concentrations which also caused some cytotoxicity.Â </p>
<p>The iloperidone metabolite P95 was negative in the Ames test, the V79 chromosome aberration test, and an <span class="Italics">in vivo</span> mouse bone marrow micronucleus test.</p>
<p><span class="Bold Italics">Impairment of Fertility:</span>Â Iloperidone decreased fertility at 12 and 36 mg/kg in a study in which both male and female rats were treated. The no-effect dose was 4 mg/kg, which is 1.6 times the MRHD of 24 mg/day on a mg/m<span class="Sup">2</span> basis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s14"></a><a name="section-14"></a><p></p>
<h1>14Â Â Â Â Â CLINICAL STUDIES</h1>
<p class="First">The efficacy of FANAPT in the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> was supported byÂ 2 placebo- and active-controlled short-term (4- and 6-week) trials.Â Both trials enrolled patients who met the DSM-III/IV criteria for <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>.Â </p>
<p>Two instruments were used for assessing psychiatric signs and symptoms in these studies.Â The Positive and Negative Syndrome Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS) are both multi-item inventories of general psychopathology usually used to evaluate the effects of drug treatment in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>.Â </p>
<p>A 6-week, placebo-controlled trial (n=706) involved 2 flexible dose ranges of FANAPT (12 to 16 mg/day or 20 to 24 mg/day) compared to placebo and an active-control (risperidone). For the 12 to 16 mg/day group, the titration schedule of FANAPT was 1 mg twice daily on Days 1 and 2, 2 mg twice daily on Days 3 and 4, 4 mg twice daily on Days 5 and 6, and 6 mg twice daily on Day 7. For the 20 to 24 mg/day group, the titration schedule of FANAPT was 1 mg twice daily on Day 1, 2 mg twice daily on Day 2, 4 mg twice daily on Day 3, 6 mg twice daily on Days 4 and 5, 8 mg twice daily on Day 6, and 10 mg twice daily on Day 7. The primary endpoint was change from baseline on the BPRS total score at the end of treatment (Day 42). Both the 12 to 16 mg/day and the 20 to 24 mg/day dose ranges of FANAPT were superior to placebo on the BPRS total score. The active-control antipsychotic drug appeared to be superior to FANAPT in this trial within the first 2 weeks, a finding that may in part be explained by the more rapid titration that was possible for that drug. In patients in this study who remained on treatment for at least 2 weeks, iloperidone appeared to have had comparable efficacy to the active-control.</p>
<p>A 4-week, placebo-controlled trial (n=604) involved one fixed dose of FANAPT (24 mg/day) compared to placebo- and an active-control (ziprasidone). The titration schedule for this study was similar to that for the 6-week study. This study involved titration of FANAPT starting at 1 mg twice daily on Day 1 and increasing to 2, 4, 6, 8, 10, and 12 mg twice daily on Days 2, 3, 4, 5, 6, and 7. The primary endpoint was change from baseline on the PANSS total score at the end of treatment (Day 28). The 24 mg/day FANAPT dose was superior to placebo in the PANSS total score. FANAPT appeared to have similar efficacy to the active-control drug which also needed a slow titration to the target dose.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<h1>16Â Â Â Â Â HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">FANAPT tablets are white, round and identified with a logo â€œ<img alt="Tablet Imprint " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=43452bf8-76e7-47a9-a5d8-41fe84d061f0&amp;name=fanapt-01.jpg">â€? debossed on one side and tablet strength â€œ1â€?, â€œ2â€?, â€œ4â€?, â€œ6â€?, â€œ8â€?, â€œ10â€?, or â€œ12â€? debossed on the other side. Tablets are supplied in the following strengths and package configurations:</p>
<table>
<col width="172">
<col width="232">
<col width="109">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Package Configuration</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Tablet Strength (mg)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">NDC Code</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">Bottles of 60</td>
<td class="Lrule Rrule Toprule" align="center">1 mg</td>
<td class="Lrule Rrule Toprule" align="center"> 0078-0595-20 </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">Bottles of 60</td>
<td class="Lrule Rrule Toprule" align="center">2 mg</td>
<td class="Lrule Rrule Toprule" align="center"> 0078-0596-20 </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">Bottles of 60</td>
<td class="Lrule Rrule Toprule" align="center">4 mg</td>
<td class="Lrule Rrule Toprule" align="center"> 0078-0597-20 </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">Bottles of 60</td>
<td class="Lrule Rrule Toprule" align="center">6 mg</td>
<td class="Lrule Rrule Toprule" align="center"> 0078-0598-20 </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">Bottles of 60</td>
<td class="Lrule Rrule Toprule" align="center">8 mg</td>
<td class="Lrule Rrule Toprule" align="center"> 0078-0599-20 </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">Bottles of 60</td>
<td class="Lrule Rrule Toprule" align="center">10 mg</td>
<td class="Lrule Rrule Toprule" align="center"> 0078-0600-20 </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">Bottles of 60</td>
<td class="Lrule Rrule Toprule" align="center">12 mg</td>
<td class="Lrule Rrule Toprule" align="center"> 0078-0601-20 </td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="center">Titration Pack</td>
<td class="Lrule Rrule Toprule" align="center">2x1 mg, 2x2 mg, 2x4 mg, 2x6 mg<br>(Total of 8 tablets)</td>
<td class="Lrule Rrule Toprule" align="center"> 0078-0602-08 </td>
</tr>
</tbody>
</table>
<p><span class="Bold">Storage</span></p>
<p>Store FANAPT tablets at controlled room temperature, 25Â°C (77Â°F); excursions permitted to 15Â° to 30 Â°C (59Â° to 86Â°F) [See USP Controlled Room Temperature]. Protect FANAPT tablets from exposure to light and moisture.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-16"></a><p></p>
<h1>17Â Â Â Â Â PATIENT COUNSELING INFORMATION</h1>
<p class="First">Physicians are advised to discuss the following issues with patients for whom they prescribe FANAPT: </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<h2>17.1Â Â Â Â Â QT Interval Prolongation</h2>
<p class="First">Patients should be advised to consult their physician immediately if they feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, lose consciousness or have heart <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>.Â Patients should be counseled not to take FANAPT with other drugs that cause QT interval prolongation <span class="Italics">[see Warnings and Precautions (5.2)]</span>.Â Patients should be told to inform physicians that they are taking FANAPT before any new drug is taken.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.2"></a><p></p>
<h2>17.2Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></h2>
<p class="First">Patients and caregivers should be counseled that a potentially fatal symptom complex sometimes referred to as NMS has been reported in association with administration of antipsychotic drugs, including FANAPT. Signs and symptoms of NMS include <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status, and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and cardiac dysrhythmia) <span class="Italics">[see Warnings and Precautions (5.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.3"></a><p></p>
<h2>17.3Â Â Â Â Â Metabolic Changes</h2>
<p class="First">Patients should be aware of the symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> (high blood sugar) and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. Patients who are diagnosed with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, those with risk factors for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, or those who develop these symptoms during treatment should have their blood glucose monitored at the beginning of and periodically during treatment. Patients should be counseled that <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> has occurred during treatment with FANAPT. Clinical monitoring of weight is recommended  <span class="Italics">[see Warnings and Precautions (5.5)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.4"></a><p></p>
<h2>17.4Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></h2>
<p class="First">Patients should be advised of the risk of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, particularly at the time of initiating treatment, reinitiating treatment, or increasing the dose <span class="Italics">[see Warnings and Precautions (5.7)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.5"></a><p></p>
<h2>17.5Â Â Â Â Â Interference with Cognitive and Motor Performance</h2>
<p class="First">Because FANAPT may have the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that FANAPT therapy does not affect them adverselyÂ <span class="Italics">[see Warnings and Precautions (5.</span><span class="Italics">1</span><span class="Italics">4</span><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-16.6"></a><p></p>
<h2>17.6Â Â Â Â Â Pregnancy</h2>
<p class="First">Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy with FANAPTÂ <span class="Italics">[see Use in Specific Population</span><span class="Italics">s</span><span class="Italics"> (8.1)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.7"></a><p></p>
<h2>17.7Â Â Â Â Â Nursing</h2>
<p class="First">Patients should be advised not to breastfeed an infant if they are taking FANAPTÂ <span class="Italics">[see Use in Specific Populations (8.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.8"></a><p></p>
<h2>17.8Â Â Â Â Â Concomitant Medication</h2>
<p class="First">Patients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs, since there is a potential for interactionsÂ <span class="Italics">[see Drug Interactions (7)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.9"></a><p></p>
<h2>17.9Â Â Â Â Â Alcohol</h2>
<p class="First">Patients should be advised to avoid alcohol while taking FANAPT.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.10"></a><p></p>
<h2>17.10Â Â Â Â Â Heat Exposure and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></h2>
<p class="First">Patients should be advised regarding appropriate care in avoiding overheating and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.</p>
<p>Fanapt<span class="Sup">Â®</span> is a registered trademark of Vanda Pharmaceuticals Inc. and is used by Novartis Pharmaceuticals Corporation under license.</p>
<p>Distributed by:</p>
<p>Novartis Pharmaceuticals Corporation<br>East Hanover, NJ 07936</p>
<p>T2014-48<br>April 2014</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label </span><span class="Bold">â€“</span><span class="Bold">Â </span><span class="Bold">1 mg</span></p>
<p>Rx Only
		Â Â Â Â Â 
	
		Â Â Â Â Â 
	NDC 0078-0595-20</p>
<p>FanaptÂ® </p>
<p>iloperidone tablets</p>
<p>1 mg</p>
<p>60 Tablets</p>
<p><img alt="PRINCIPAL DISPLAY PANEL
Package Label â€“ 1 mg
Rx Only		NDC 0078-0595-20
FanaptÂ® 
iloperidone tablets
1 mg
60 Tablets
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=43452bf8-76e7-47a9-a5d8-41fe84d061f0&amp;name=fanapt-03.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label </span><span class="Bold">â€“</span><span class="Bold">Â </span><span class="Bold">2 mg</span></p>
<p>Rx Only
		Â Â Â Â Â 
	
		Â Â Â Â Â 
	NDC 0078-0596-20</p>
<p>FanaptÂ® </p>
<p>iloperidone tablets</p>
<p>2 mg</p>
<p>60 Tablets</p>
<p><img alt="PRINCIPAL DISPLAY PANEL
Package Label â€“ 2 mg
Rx Only		NDC 0078-0596-20
FanaptÂ® 
iloperidone tablets
2 mg
60 Tablets
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=43452bf8-76e7-47a9-a5d8-41fe84d061f0&amp;name=fanapt-04.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label </span><span class="Bold">â€“</span><span class="Bold">Â </span><span class="Bold">4 mg</span></p>
<p>Rx Only
		Â Â Â Â Â 
	
		Â Â Â Â Â 
	NDC 0078-0597-20</p>
<p>FanaptÂ® </p>
<p>iloperidone tablets</p>
<p>4 mg</p>
<p>60 Tablets</p>
<p><img alt="PRINCIPAL DISPLAY PANEL
Package Label â€“ 4 mg
Rx Only		NDC 0078-0597-20
FanaptÂ® 
iloperidone tablets
4 mg
60 Tablets
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=43452bf8-76e7-47a9-a5d8-41fe84d061f0&amp;name=fanapt-05.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label </span><span class="Bold">â€“</span><span class="Bold">Â </span><span class="Bold">6 mg</span></p>
<p>Rx Only
		Â Â Â Â Â 
	
		Â Â Â Â Â 
	NDC 0078-0598-20</p>
<p>FanaptÂ® </p>
<p>iloperidone tablets</p>
<p>6 mg</p>
<p>60 Tablets</p>
<p><img alt="PRINCIPAL DISPLAY PANEL
Package Label â€“ 6 mg
Rx Only		NDC 0078-0598-20
FanaptÂ® 
iloperidone tablets
6 mg
60 Tablets
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=43452bf8-76e7-47a9-a5d8-41fe84d061f0&amp;name=fanapt-06.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-21"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label </span><span class="Bold">â€“</span><span class="Bold">Â </span><span class="Bold">8 mg</span></p>
<p>Rx Only
		Â Â Â Â Â 
	
		Â Â Â Â Â 
	NDC 0078-0599-20</p>
<p>FanaptÂ® </p>
<p>Iloperidone tablets</p>
<p>8 mg</p>
<p>60 Tablets</p>
<p><img alt="PRINCIPAL DISPLAY PANEL
Package Label â€“ 8 mg
Rx Only		NDC 0078-0599-20
FanaptÂ® 
Iloperidone tablets
8 mg
60 Tablets
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=43452bf8-76e7-47a9-a5d8-41fe84d061f0&amp;name=fanapt-07.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-22"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label </span><span class="Bold">â€“</span><span class="Bold">Â </span><span class="Bold">10 mg</span></p>
<p>Rx Only
		Â Â Â Â Â 
	
		Â Â Â Â Â 
	NDC 0078-0600-20</p>
<p>FanaptÂ® </p>
<p>Iloperidone tablets</p>
<p>10 mg</p>
<p>60 Tablets</p>
<p><img alt="PRINCIPAL DISPLAY PANEL
Package Label â€“ 10 mg
Rx Only		NDC 0078-0600-20
FanaptÂ® 
Iloperidone tablets
10 mg
60 Tablets
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=43452bf8-76e7-47a9-a5d8-41fe84d061f0&amp;name=fanapt-08.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-23"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label </span><span class="Bold">â€“</span><span class="Bold">Â </span><span class="Bold">12 mg</span></p>
<p>Rx Only
		Â Â Â Â Â 
	
		Â Â Â Â Â 
	NDC 0078-0601-20</p>
<p>FanaptÂ® </p>
<p>Iloperidone tablets</p>
<p>12 mg</p>
<p>60 Tablets</p>
<p><img alt="PRINCIPAL DISPLAY PANEL
Package Label â€“ 12 mg
Rx Only		NDC 0078-0601-20
FanaptÂ® 
Iloperidone tablets
12 mg
60 Tablets
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=43452bf8-76e7-47a9-a5d8-41fe84d061f0&amp;name=fanapt-09.jpg"><br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-24"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label </span><span class="Bold">â€“ TITRATION PACK</span></p>
<p>Rx Only
		Â Â Â Â Â 
	
		Â Â Â Â Â 
	NDC 0078-0602-08</p>
<p>FanaptÂ® </p>
<p>Iloperidone tablets</p>
<p>This pack contains:</p>
<p>Two 1-mg tablets</p>
<p>Two 2-mg tablets</p>
<p>Two 4-mg tablets</p>
<p>Two 6-mg tablets</p>
<p>8 Tablets</p>
<p><img alt="PRINCIPAL DISPLAY PANEL
Package Label â€“ TITRATION PACK
Rx Only		NDC 0078-0602-08
FanaptÂ® 
Iloperidone tablets
This pack contains:
Two 1-mg tablets
Two 2-mg tablets
Two 4-mg tablets
Two 6-mg tablets
8 Tablets
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=43452bf8-76e7-47a9-a5d8-41fe84d061f0&amp;name=fanapt-0A.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FANAPTÂ 		
					</strong><br><span class="contentTableReg">iloperidone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0078-0595</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ILOPERIDONE</strong> (ILOPERIDONE) </td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">1Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (round, flat, beveled-edged) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0595-20</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FANAPTÂ 		
					</strong><br><span class="contentTableReg">iloperidone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0078-0596</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ILOPERIDONE</strong> (ILOPERIDONE) </td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">2Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">2</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0596-20</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FANAPTÂ 		
					</strong><br><span class="contentTableReg">iloperidone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0078-0597</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ILOPERIDONE</strong> (ILOPERIDONE) </td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">4Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0597-20</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FANAPTÂ 		
					</strong><br><span class="contentTableReg">iloperidone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0078-0598</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ILOPERIDONE</strong> (ILOPERIDONE) </td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">6Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">6</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0598-20</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FANAPTÂ 		
					</strong><br><span class="contentTableReg">iloperidone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0078-0599</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ILOPERIDONE</strong> (ILOPERIDONE) </td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">8Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">1mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">8</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0599-20</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FANAPTÂ 		
					</strong><br><span class="contentTableReg">iloperidone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0078-0600</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ILOPERIDONE</strong> (ILOPERIDONE) </td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">10Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">10</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0600-20</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FANAPTÂ 		
					</strong><br><span class="contentTableReg">iloperidone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0078-0601</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ILOPERIDONE</strong> (ILOPERIDONE) </td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">12Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">12</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0601-20</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FANAPTÂ 		
					</strong><br><span class="contentTableReg">iloperidone kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0078-0602</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0602-08</td>
<td class="formItem">1  in 1 DOSE PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">PartÂ #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem"> </td>
<td class="formItem">2Â </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem"> </td>
<td class="formItem">2Â </td>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 3</strong></td>
<td class="formItem"> </td>
<td class="formItem">2Â </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 4</strong></td>
<td class="formItem"> </td>
<td class="formItem">2Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>FANAPTÂ 		
					</strong><br><span class="contentTableReg">iloperidone tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ILOPERIDONE</strong> (ILOPERIDONE) </td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">1Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>FANAPTÂ 		
					</strong><br><span class="contentTableReg">iloperidone tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ILOPERIDONE</strong> (ILOPERIDONE) </td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">2Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">2</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 3 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>FANAPTÂ 		
					</strong><br><span class="contentTableReg">iloperidone tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ILOPERIDONE</strong> (ILOPERIDONE) </td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">4Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 4 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>FANAPTÂ 		
					</strong><br><span class="contentTableReg">iloperidone tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ILOPERIDONE</strong> (ILOPERIDONE) </td>
<td class="formItem">ILOPERIDONE</td>
<td class="formItem">6Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">6</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022192</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Novartis Pharmaceuticals Corporation
							(002147023)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>22ae60cc-b992-4b87-8e70-c217ce57cd0c</div>
<div>Set id: 43452bf8-76e7-47a9-a5d8-41fe84d061f0</div>
<div>Version: 5</div>
<div>Effective Time: 20140421</div>
</div>
</div>Â <div class="DistributorName">Novartis Pharmaceuticals Corporation</div></p>
</body></html>
